| Revenue growth | 29% YoY in Q1FY27 |
|---|---|
| Margins | EBITDA margin at 31.8%; guiding >30% from FY27+ |
| Order book | Healthy order book and internal pipeline mentioned |
| Demand visibility | Strong visibility on CDMO and commercial API pipelines |
| Management confidence | High; visibility on late-stage projects and commercial API supplies |
Growth
Revenue grew 29% YoY; EBITDA increased 66% YoY to ₹644 Cr; Net Profit surged 126% YoY to ₹368 Cr.
Outlook
Management guiding >30% EBITDA margins from FY27+. Cumulative CAPEX >₹3,000 Cr planned over FY27-28 to drive long-term growth.
Risks
Potential macro-economic volatility, currency fluctuations, and regulatory trends in global pharmaceutical markets.
Last quarter's promises, checked
Delivered
- Guided ROCE ~17.7% → delivered 19% (= BEAT)
- Guided ARV revenue mix to stay below 1/3 → delivered 33% (= BEAT)
- Guided FY27 capex INR 1,500 Cr → delivered INR 2,000 Cr guidance (= BEAT)
Partly delivered
- Guided Asset Turnover target >1.0x → delivered "almost there" (= PARTIAL)
Investor Presentation filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,052.80
- Market cap
- ₹1,10,915 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 101.4×Sector 47.3×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Other Announcement
Laurus Labs has been assigned an ESG score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited.
Laurus Labs Employee Stock Options
Laurus Labs has allotted 62,635 equity shares to employees upon the exercise of vested stock options under its ESOP schemes.
Laurus Labs Merger & Restructuring
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Results Update
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.
Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered a strong Q1 FY27 with ₹2,026 Cr revenue (up 29% YoY), driven by robust CDMO growth. EBITDA margins expanded to 31.8% due to favorable product mix and operational leverage.